As drug approvals dive in 2016, returns on R&D deteriorate

LONDON (Reuters) - The global pharmaceuticals industry is set to win the lowest annual number of new drug approvals this year since 2010 and a new report on Tuesday suggests drugmakers' returns on research investment are deteriorating.